Literature DB >> 17402995

Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident.

N S Abraham1, H B El-Serag, C Hartman, P Richardson, A Deswal.   

Abstract

AIM: To assess degree of cyclooxygenase-2 (COX-2) selectivity of a non-steroidal anti-inflammatory drug (NSAID) and risk of myocardial infarction (MI) or cerebrovascular accident (CVA).
METHODS: Prescription fill data were linked to medical records of a merged VA-Medicare dataset. NSAIDs were categorized by Cox-2 selectivity. Incidence of CVA and MI within 180 days of index prescription was assessed using Cox-proportional hazards models adjusted for gender, race, cardiovascular and pharmacological risk factors and propensity for prescription of highly COX-2 selective NSAIDs.
RESULTS: Of 384,322 patients (97.5% men and 85.4% white), 79.4% were prescribed a poorly selective, 16.4% a moderately selective and 4.2% a highly selective NSAID. There were 985 incident cases of MI and 586 cases of CVA in >145 870 person-years. Highly selective agents had the highest rate of MI (12.3 per 1000 person-years; [95% CI: 12.2-12.3]) and CVA (8.1 per 1000 person-years; [95% CI: 8.0-8.2]). Periods without NSAID exposure were associated with lowest risk. In adjusted models, highly selective COX-2 selective NSAIDs were associated with a 61% increase in CVA and a 47% increase in MI, when compared with poorly selective NSAIDs.
CONCLUSIONS: The risk of MI and CVA increases with any NSAID. Highly COX-2 selective NSAIDs confer the greatest risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17402995     DOI: 10.1111/j.1365-2036.2007.03292.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  28 in total

1.  Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance.

Authors:  Johanne Brooks; Richard Warburton; Ian L P Beales
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

2.  Time to reappraise the therapeutic place of celecoxib.

Authors:  Ian L P Beales
Journal:  Ther Adv Chronic Dis       Date:  2018-01-03       Impact factor: 5.091

3.  To evaluate the effect of combining photo-activation therapy with platelet-rich plasma injections for the novel treatment of osteoarthritis.

Authors:  Julien Ben Freitag; Adele Barnard
Journal:  BMJ Case Rep       Date:  2013-03-26

Review 4.  Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.

Authors:  Leyte L Winfield; Florastina Payton-Stewart
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

5.  Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques.

Authors:  J A Sonnen; E B Larson; R L Walker; S Haneuse; P K Crane; S L Gray; J C S Breitner; T J Montine
Journal:  Neurology       Date:  2010-09-01       Impact factor: 9.910

6.  Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study.

Authors:  Yaa-Hui Dong; Chia-Hsuin Chang; Li-Chiu Wu; Jing-Shiang Hwang; Sengwee Toh
Journal:  Br J Clin Pharmacol       Date:  2018-03-13       Impact factor: 4.335

7.  Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases.

Authors:  Stephanie J Reisinger; Patrick B Ryan; Donald J O'Hara; Gregory E Powell; Jeffery L Painter; Edward N Pattishall; Jonathan A Morris
Journal:  J Am Med Inform Assoc       Date:  2010 Nov-Dec       Impact factor: 4.497

8.  Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2.

Authors:  Jianxiong Jiang; Thota Ganesh; Yuhong Du; Yi Quan; Geidy Serrano; Min Qui; Iris Speigel; Asheebo Rojas; Nadia Lelutiu; Raymond Dingledine
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

Review 9.  Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice.

Authors:  José Pedro Henriques Patrício; Jorge Pinto Pereira Barbosa; Rui Miguel Monteiro Ramos; Nuno Filipe Pimenta Antunes; Pedro Carlos Santos de Melo
Journal:  Clin Drug Investig       Date:  2013-03       Impact factor: 2.859

Review 10.  Emerging roles of PGE2 receptors in models of neurological disease.

Authors:  Katrin Andreasson
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-04-11       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.